The world is pegged by the deadliest epidemic humanity has ever witnessed in the form of Novel Coronavirus- SARS COV-2. This respiratory syndrome virus has been highly adaptive to weather changes and immunization to the body as it has been rapidly regenerative and has spread and contracted millions of people across the world. Although the virus has been staggered when it comes to the mortality rate with people having high blood sugar, respiratory disorders like COPD and liver function disorders being the most vulnerable to the virus.
The United States of America, Brazil, India, the prime European Countries and China has emerged as the hotbeds for the virus with a majority of the cases being reported from the above-mentioned Territories. National Emergency shutdowns and closure of all business exchange activities and transportation activities have come to a complete standstill as the world grapples with one of the biggest crisis ever witnessed.
Amid this crisis, scientists, pharmacists and infectious diseases experts from all across the world have come together on a common platform and decided to work on the production of a vaccine. While some medication therapies have yielded minor results like Azithromyecein and Hydroxychloroquine, their efficacy has not been paramount to resolve the issue completely. However, there have been occasional glimmers of hope with the news that some vaccines have passed the initial trials and have shown considerable progress in the most affected population of the sample tests.
One of them which is doing the rounds now is the vaccine hAd5- Covid 19 Vaccine which was manufactured by the genetical engineering firm Immunity Bio. The vaccine molecule leads to the development of an outer spike (S) protein, which is in turn used to activate antibodies against the coronavirus (SARS-CoV-2). These bi-polar constructs (bivalent sequences) of SARS-CoV-2 offer the hAd5 vaccine the opportunity to provide recipients with durable, long-term cell-mediated immunity with active antibody stimulation against both the S and N proteins.
The company has decided to launch a Phase I clinical trial at Irvine, California-based Hoag Hospital this month. Adult subjects up to the age of 55 have. decided to volunteer for the clinical trial and the first stage of the trial would point out the deficiencies of the vaccine and how they can be overcome to ensure that the vaccine can stand out among the ones clinically manufactured after its predecessors.
The manufacturers of the vaccine have claimed that Immunity Bio, the manufacturing firm has plans to administer the hAd5-COVID-19 vaccine combining the effects of both a prime and a booster dosage to elongate the protection chain against SARS-CoV-2 since multiple re-immunizations using the same prevalent platform is now possible with the novel hAd5. The company is also pursuing preclinical development for oral, inhalation and intranasal administration to provide immunity to the mucosa related disorders in addition to effective humoral and cell-transpired immunity against COVID-19 virus.
The manufacturing firm ImmunityBio is working in collaboration with American firm Nantkwest, which is looking after the cost related to the engineering and manufacturing of the requisite vaccine which must then be prepared for mass inoculation. The main aim of this collaboration is to ration the cost burden and allocate individual cost heads so that the excessive expenditure can be handled with aplomb.
The collaborating firm NantKwest is looking to make a stem cell therapy which would formally reduce the amount of time that a patient spends on a ventilator. By making such a therapeutic device for treatment of critical disorders, they would make it more feasible for the patients to access the equipment directly from their homes and also ensure that they can get the facilities without moving an inch from the place to which they are restricted.
Thus, it is pretty clear that to fight this common enemy the entire human race has to come together on a platform and ensure that the scientists are on an equal footing. Joint efforts and cooperative tendencies would be the crucial component that would guide this race to find the perfect vaccine for Covid 19, a menace that has persisted for too long and has caused too much damage. To restrict any further catastrophe, taking clear steps to identify the problems on a fast track basis and then sorting out solutions would be the key to survival.